ESTA
Establishment Labs Holdings Inc. [ESTA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ESTA Stock Summary
Top 10 Correlated ETFs
ESTA
Top 10 Correlated Stocks
ESTA
In the News
Why Establishment Labs Stock Is Crashing Today
Establishment Labs missed consensus revenue and earnings estimates in Q3. The company also slashed its full-year guidance.
Establishment Labs Holdings Inc. (ESTA) Q3 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Juan Jose Chacon Quiros - Founder and Chief Executive Officer Raj Denhoy - Chief Financial Officer Conference Call Participants Mike Sarcone - Jefferies Allen Gong - JPMorgan Anthony Petrone - Mizuho Group Josh Jennings - TD Cowen Neil Chatterji - B. Riley Joanne Wuensch - Citibank Sam Eiber - BTIG George Sellers - Stephens Operator Good afternoon.
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Establishment Labs Holdings Inc. (ESTA): Can Its 14.3% Jump Turn into More Strength?
Establishment Labs Holdings Inc. (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Establishment Labs Holdings Inc. (ESTA) Q2 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan José Chacón-Quirós - Chief Executive Officer Conference Call Participants Young Li - Jefferies Anthony Petrone - Mizuho Group Josh Jennings - Cowen & Company Sam Eiber - BTIG Neil Chatterji - B. Riley George Sellers - Stephens Operator Good afternoon.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.90 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.24 per share a year ago.
Establishment Labs Holdings Inc. (ESTA) Stock Jumps 6.1%: Will It Continue to Soar?
Establishment Labs Holdings Inc. (ESTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What's Going On With Block Shares?
Block shares are making headlines for all the wrong reasons today, with short-seller Hindenburg Research raising red flags surrounding the company. Whose side are you on?
ESTA Financial details
ESTA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.53 | 4.36 | 3.63 | 5.28 | 6.61 | |
| Net income per share | -1.22 | -1.86 | -1.63 | -1.72 | -3.08 | |
| Operating cash flow per share | -1.95 | -1.46 | -0.54 | -1.15 | -2.13 | |
| Free cash flow per share | -2.06 | -1.8 | -0.7 | -1.43 | -3.53 | |
| Cash per share | 3.03 | 1.83 | 3.63 | 2.23 | 2.71 | |
| Book value per share | 4 | 1.93 | 3.21 | 2.12 | -0.33 | |
| Tangible book value per share | 3.78 | 1.74 | 3.02 | 1.91 | -0.54 | |
| Share holders equity per share | 4 | 1.93 | 3.21 | 2.12 | -0.33 | |
| Interest debt per share | 2.1 | 2.78 | 2.66 | 2.64 | 7.81 | |
| Market cap | 475.76M | 568.18M | 877.62M | 1.62B | 1.61B | |
| Enterprise value | 445.44M | 578.67M | 844.85M | 1.62B | 1.72B | |
| P/E ratio | -22.55 | -14.89 | -23.02 | -39.39 | -21.35 | |
| Price to sales ratio | 7.77 | 6.34 | 10.36 | 12.79 | 9.93 | |
| POCF ratio | -14.04 | -18.95 | -70.15 | -58.85 | -30.78 | |
| PFCF ratio | -13.34 | -15.36 | -53.46 | -47.29 | -18.58 | |
| P/B Ratio | 6.85 | 14.34 | 11.71 | 31.93 | -196.17 | |
| PTB ratio | 6.85 | 14.34 | 11.71 | 31.93 | -196.17 | |
| EV to sales | 7.28 | 6.46 | 9.98 | 12.79 | 10.62 | |
| Enterprise value over EBITDA | -16.98 | -18 | -27.63 | -51.64 | -40.19 | |
| EV to operating cash flow | -13.15 | -19.3 | -67.53 | -58.87 | -32.93 | |
| EV to free cash flow | -12.49 | -15.65 | -51.46 | -47.3 | -19.88 | |
| Earnings yield | -0.04 | -0.07 | -0.04 | -0.03 | -0.05 | |
| Free cash flow yield | -0.07 | -0.07 | -0.02 | -0.02 | -0.05 | |
| Debt to equity | 0.4 | 1.22 | 0.7 | 1.07 | -21.91 | |
| Debt to assets | 0.24 | 0.42 | 0.34 | 0.39 | 0.85 | |
| Net debt to EBITDA | 1.16 | -0.33 | 1.07 | -0.01 | -2.63 | |
| Current ratio | 6.05 | 4.12 | 5.11 | 3.55 | 3.85 | |
| Interest coverage | -2.71 | -3.56 | -2.98 | -2.77 | -3.37 | |
| Income quality | 1.61 | 0.79 | 0.33 | 0.67 | 0.69 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.77 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.21 | 0.17 | 0.16 | 0.14 | 0.13 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Capex to operating cash flow | 0.05 | 0.23 | 0.31 | 0.24 | 0.66 | |
| Capex to revenue | -0.03 | -0.08 | -0.05 | -0.05 | -0.21 | |
| Capex to depreciation | -0.63 | -2.13 | -1.05 | -1.63 | -7.9 | |
| Stock based compensation to revenue | 0.12 | 0.07 | 0.07 | 0.08 | 0.08 | |
| Graham number | 10.47 | 8.98 | 10.88 | 9.04 | 4.81 | |
| ROIC | -0.25 | -0.36 | -0.22 | -0.24 | -0.23 | |
| Return on tangible assets | -0.19 | -0.34 | -0.25 | -0.31 | -0.37 | |
| Graham Net | 1.8 | -0.38 | 1.25 | -0.12 | -4.42 | |
| Working capital | 82.99M | 72.6M | 106.4M | 81.38M | 110.95M | |
| Tangible asset value | 65.58M | 35.71M | 70.35M | 45.9M | -13.26M | |
| Net current asset value | 52.35M | 18.92M | 50.87M | 24.48M | -69.34M | |
| Invested capital | 0.4 | 1.22 | 0.7 | 1.07 | -21.91 | |
| Average receivables | 15.38M | 20.21M | 20.95M | 21.78M | 29.93M | |
| Average payables | 7.69M | 8.3M | 10.04M | 12.1M | 17.25M | |
| Average inventory | 19.01M | 26.75M | 25.94M | 25.81M | 32.5M | |
| Days sales outstanding | 105.24 | 92.78 | 82.45 | 70.41 | 79.96 | |
| Days payables outstanding | 90.76 | 109.02 | 110.29 | 127.99 | 132.7 | |
| Days of inventory on hand | 361.44 | 301.43 | 263.31 | 251.19 | 242.32 | |
| Receivables turnover | 3.47 | 3.93 | 4.43 | 5.18 | 4.56 | |
| Payables turnover | 4.02 | 3.35 | 3.31 | 2.85 | 2.75 | |
| Inventory turnover | 1.01 | 1.21 | 1.39 | 1.45 | 1.51 | |
| ROE | -0.3 | -0.96 | -0.51 | -0.81 | 9.19 | |
| Capex per share | -0.1 | -0.34 | -0.17 | -0.28 | -1.4 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.56 | 1.78 | 1.89 | 1.9 | 1.48 | |
| Net income per share | -0.76 | -0.55 | -0.48 | -0.65 | -1.12 | |
| Operating cash flow per share | -0.9 | -0.57 | -0.84 | -1.1 | 0 | |
| Free cash flow per share | -1.09 | -0.99 | -1.01 | -1.46 | 0 | |
| Cash per share | 2.67 | 2.7 | 1.74 | 3.52 | 2 | |
| Book value per share | 0.06 | -0.33 | -0.65 | 2.14 | 1.17 | |
| Tangible book value per share | -0.15 | -0.54 | -0.84 | 1.96 | 0.93 | |
| Share holders equity per share | 0.06 | -0.33 | -0.65 | 2.14 | 1.17 | |
| Interest debt per share | 6.36 | 7.38 | 7.56 | 7.4 | 7.09 | |
| Market cap | 1.34B | 1.62B | 1.67B | 1.76B | 1.28B | |
| Enterprise value | 1.42B | 1.73B | 1.81B | 1.85B | 1.41B | |
| P/E ratio | -17.98 | -29.78 | -35 | -26.24 | -10.91 | |
| Price to sales ratio | 35 | 36.88 | 35.93 | 36.19 | 33.18 | |
| POCF ratio | -60.9 | -115.27 | -81.1 | -62.23 | 0 | |
| PFCF ratio | -49.97 | -66.1 | -67.16 | -47.13 | 0 | |
| P/B Ratio | 881.22 | -197.4 | -104.51 | 32.03 | 41.9 | |
| PTB ratio | 881.22 | -197.4 | -104.51 | 32.03 | 41.9 | |
| EV to sales | 37.25 | 39.44 | 38.92 | 38.15 | 36.71 | |
| Enterprise value over EBITDA | -100.87 | -163.9 | -246.18 | -151.84 | -67.19 | |
| EV to operating cash flow | -64.82 | -123.29 | -87.85 | -65.6 | 0 | |
| EV to free cash flow | -53.18 | -70.69 | -72.75 | -49.68 | 0 | |
| Earnings yield | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Free cash flow yield | -0.02 | -0.02 | -0.01 | -0.02 | 0 | |
| Debt to equity | 100.11 | -21.91 | -11.43 | 3.39 | 6.17 | |
| Debt to assets | 0.81 | 0.85 | 0.87 | 0.65 | 0.7 | |
| Net debt to EBITDA | -6.1 | -10.65 | -18.93 | -7.79 | -6.47 | |
| Current ratio | 4.27 | 3.85 | 3.43 | 4.83 | 3.71 | |
| Interest coverage | -2.71 | -5.98 | -2.17 | -3.79 | 5.72 | |
| Income quality | 1.18 | 1.03 | 1.73 | 1.69 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.14 | 0.15 | 0.14 | 0.14 | 0.19 | |
| Intangibles to total assets | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0.22 | 0.74 | 0.21 | 0.32 | 0 | |
| Capex to revenue | -0.13 | -0.24 | -0.09 | -0.19 | 0 | |
| Capex to depreciation | -4.36 | -9.09 | -3.84 | -8.02 | 0 | |
| Stock based compensation to revenue | 0.08 | 0.07 | 0.07 | 0.07 | 0 | |
| Graham number | 1.03 | 2.03 | 2.66 | 5.61 | 5.44 | |
| ROIC | -0.07 | -0.08 | -0.05 | -0.06 | -0.09 | |
| Return on tangible assets | -0.1 | -0.07 | -0.06 | -0.06 | -0.11 | |
| Graham Net | -3.33 | -4.39 | -5.21 | -2.87 | -4.34 | |
| Working capital | 105.79M | 110.95M | 100.57M | 165.74M | 136.42M | |
| Tangible asset value | -3.58M | -13.26M | -20.83M | 50.18M | 24.32M | |
| Net current asset value | -47.97M | -69.34M | -83.31M | -21.41M | -53.33M | |
| Invested capital | 100.11 | -21.91 | -11.43 | 3.39 | 6.17 | |
| Average receivables | 31.62M | 33.33M | 38.24M | 46.22M | 53.04M | |
| Average payables | 15.43M | 17.46M | 20.14M | 22.31M | 26.64M | |
| Average inventory | 29.04M | 34.07M | 41.36M | 51.26M | 62.15M | |
| Days sales outstanding | 73.53 | 72.77 | 79.41 | 95.25 | 127.83 | |
| Days payables outstanding | 109.71 | 115.23 | 110.85 | 119.8 | 209.05 | |
| Days of inventory on hand | 232.7 | 210.41 | 252.52 | 277.23 | 490.94 | |
| Receivables turnover | 1.22 | 1.24 | 1.13 | 0.94 | 0.7 | |
| Payables turnover | 0.82 | 0.78 | 0.81 | 0.75 | 0.43 | |
| Inventory turnover | 0.39 | 0.43 | 0.36 | 0.32 | 0.18 | |
| ROE | -12.25 | 1.66 | 0.75 | -0.31 | -0.96 | |
| Capex per share | -0.2 | -0.42 | -0.17 | -0.35 | 0 |
ESTA Frequently Asked Questions
What is Establishment Labs Holdings Inc. stock symbol ?
Establishment Labs Holdings Inc. is a CR stock and trading under the symbol ESTA
Is Establishment Labs Holdings Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $98.5. The lowest prediction is $87 and the highest is $110
What is ESTA stock prediction ?
What is Establishment Labs Holdings Inc. stock quote today ?
Establishment Labs Holdings Inc. stock price is $24.86 today.
Is Establishment Labs Holdings Inc. stock public?
Yes, Establishment Labs Holdings Inc. is a publicly traded company.
Company Profile
- Volume Average 504.42K
- Market Capitalization 649.08M
- Employee 958
- CEO Mr. Juan Jose Chacon Quiros
- Headquarters Alajuela,CR
- IPO Date 2018-07-19
-
Website
https://www.establishmentlabs.com 
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
